The effect of mental health conditions on the use of oral anticoagulation therapy in patients with atrial fibrillation: the FinACAF study.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
05 05 2022
Historique:
received: 31 08 2021
revised: 14 10 2021
accepted: 19 10 2021
pubmed: 23 10 2021
medline: 10 5 2022
entrez: 22 10 2021
Statut: ppublish

Résumé

Little is known about the effects of mental health conditions (MHCs) on the utilization of oral anticoagulation (OAC) therapy in atrial fibrillation (AF) patients. We aimed to assess whether MHCs affect initiation of OAC therapy among AF patients with special focus on non-vitamin K antagonist oral anticoagulants (NOACs). The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) registry included all 239 222 patients diagnosed with incident AF during 2007-18 in Finland identified from national registries covering primary to tertiary care and drug purchases. Patients with previous depression, bipolar disorder, anxiety disorder, or schizophrenia diagnosis or a fulfilled psychiatric medication prescription within the year preceding the AF diagnosis were classified to have any MHC. The main outcome was OAC initiation, defined as first fulfilled OAC prescription after AF diagnosis. The patients' mean age was 72.7 years and 49.8% were female. The prevalence of any MHC was 19.9%. A lower proportion of patients with any MHC compared with those without MHCs were initiated on OAC therapy (64.9% vs. 73.3%, P < 0.001). Any MHC was associated with lower incidence of OAC initiation [adjusted subdistribution hazard ratio (aSHR) 0.867; 95% confidence interval (CI) 0.856-0.880], as were depression (aSHR 0.868; 95% CI 0.856-0.880), bipolar disorder (aSHR 0.838; 95% CI 0.824-0.852), anxiety disorder (aSHR 0.840; 95% CI 0.827-0.854), and schizophrenia (aSHR 0.838; 95% CI 0.824-0.851), during the entire follow-up. Any MHC remained associated with impaired incidence of OAC initiation also in the NOAC era during 2015-18 (aSHR 0.821; 95% CI 0.805-0.837). MHCs are common among AF patients, and they are associated with a lower rate of OAC initiation even during the NOAC era.

Identifiants

pubmed: 34677571
pii: 6408462
doi: 10.1093/ehjqcco/qcab077
pmc: PMC9071518
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-276

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Stroke. 2013 Nov;44(11):3103-8
pubmed: 23982711
Eur Psychiatry. 2009 Sep;24(6):412-24
pubmed: 19682863
Eur Psychiatry. 2017 Jun;43:109-115
pubmed: 28391102
Am J Prev Cardiol. 2021 Jun 27;7:100221
pubmed: 34611647
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
PLoS One. 2017 Apr 20;12(4):e0175975
pubmed: 28426737
BMJ Open. 2017 Dec 06;7(12):e018209
pubmed: 29217725
JAMA Cardiol. 2016 Apr 1;1(1):65-72
pubmed: 27437657
BMC Psychiatry. 2008 Sep 25;8:84
pubmed: 18817565
Am J Cardiol. 2014 Aug 15;114(4):583-6
pubmed: 25001151
N Engl J Med. 1998 May 21;338(21):1516-20
pubmed: 9593791
PLoS One. 2013;8(1):e55176
pubmed: 23372832
J Am Geriatr Soc. 2013 Dec;61(12):2236-2237
pubmed: 24329827
Nat Rev Cardiol. 2021 Feb;18(2):136-145
pubmed: 33128044
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
Health Psychol. 2014 Jul;33(7):588-96
pubmed: 23815766
Am J Manag Care. 2015 Nov 01;21(11):e609-17
pubmed: 26735294
J Gen Intern Med. 2014 Jun;29(6):855-61
pubmed: 24549520
JAMA. 2000 Jan 26;283(4):506-11
pubmed: 10659877
J Psychopharmacol. 2010 Nov;24(4 Suppl):61-8
pubmed: 20923921
Am J Manag Care. 2011 Sep;17(9):617-24
pubmed: 21902447
J Thromb Haemost. 2010 Oct;8(10):2182-91
pubmed: 20653840
Curr Opin Psychiatry. 2013 Sep;26(5):446-52
pubmed: 23880592
BMJ Open. 2021 May 31;11(5):e048839
pubmed: 34059516
Med Care. 2020 Mar;58(3):216-224
pubmed: 31876644
JAMA Netw Open. 2021 May 3;4(5):e2110096
pubmed: 33999163
Chest. 2007 Oct;132(4):1259-64
pubmed: 17646231
World Psychiatry. 2015 Jun;14(2):119-36
pubmed: 26043321
J Gen Intern Med. 2013 Oct;28(10):1333-9
pubmed: 23620189
J Gen Intern Med. 2005 Dec;20(12):1114-9
pubmed: 16423100
PLoS One. 2011;6(9):e24597
pubmed: 21935426

Auteurs

Jussi Jaakkola (J)

Heart Center, Turku University Hospital, and University of Turku, Hämeentie 11, Turku, Finland.
Heart Unit, Satakunta Central Hospital, Sairaalantie 3, FI-28500 Pori, Finland.

Konsta Teppo (K)

Heart Center, Turku University Hospital, and University of Turku, Hämeentie 11, Turku, Finland.

Fausto Biancari (F)

Heart and Lung Center, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.
Research Unit of Surgery, Anesthesia and Critical Care, University of Oulu, Kajaanintie 50, Oulu, Finland.
Clinica Montevergine, GVM Care & Research, Via Mario Malzoni 5, Mercogliano, Italy.

Olli Halminen (O)

Department of Industrial Engineering and Management, Aalto University, Espoo, Finland.

Jukka Putaala (J)

Department of Neurology, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.

Pirjo Mustonen (P)

Heart Center, Turku University Hospital, and University of Turku, Hämeentie 11, Turku, Finland.

Jari Haukka (J)

Department of Population Health, University of Helsinki, Yliopistonkatu 4, Helsinki, Finland.

Miika Linna (M)

Department of Neurology, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.
Department of Health and Social Management, University of Eastern Finland, Yliopistonranta 1, Kuopio, Finland.

Janne Kinnunen (J)

Department of Neurology, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.

Paula Tiili (P)

Department of Neurology, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.

Aapo L Aro (AL)

Heart and Lung Center, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.

Juha Hartikainen (J)

Heart Center, Kuopio University Hospital, Puijonlaaksontie 2, Kuopio, Finland.

K E Juhani Airaksinen (KEJ)

Heart Center, Turku University Hospital, and University of Turku, Hämeentie 11, Turku, Finland.

Mika Lehto (M)

Heart and Lung Center, Helsinki University Hospital, and University of Helsinki, Haartmaninkatu 4, Helsinki, Finland.
Department of Internal Medicine, Lohja Hospital, Sairaalatie 8, Lohja, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH